Cholesterolemia

(redirected from hypercholesterolemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

Cholesterolemia

 

(also cholesterinemia), the cholesterol content in blood. A high cholesterol level, or hypercholesterolemia, is found to be associated with the nephrotic syndrome, cholangitis, and some metabolic diseases, including atherosclerosis, diabetes mellitus, and podagra. A low level of cholesterol, or hypocholesterolemia, is observed in such diseases as thyrotoxicosis, Addison’s disease, and colitis.

References in periodicals archive ?
Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry.
Conclusions: Carotid intima-media thickness in hypercholesterolemia patients was increased and carotid bifurcation was site that has shown greater increase in intima-media thickness and plaques in these patients predict high risk for atherosclerosis.
The type specific primer sequence for different exons used for the identifying the samples with familial hypercholesterolemia are as following (a) Sense (b) Antisense.
Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
For hypercholesterolemia group, the LDLC levels for the TT genotype was found to be 5.
To explore the effect of clotting factors in pediatric CHD pathogenesis, we investigated the behavior of sCD40L and clotting activation in children and adolescents with hypercholesterolemia.
The report reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) by companies and universities/research institutes based on information derived from company and industry-specific sources
Currently, of all the conventional drugs available to treat hypercholesterolemia, statins bring about the maximum reduction in LDL cholesterol levels.
Familial hypercholesterolemia, one type of autosomal dominant hypercholesterolemia, is classified as either heterozygous or homozygous.
Sales forecasts of products expected to enter the market in 2015 Opdivo (nivolumab) Melanoma (Bristol-Myers Squibb) Praluent (alirocumab) Hypercholesterolemia (Regeneron and Sanoti) LCZ-696 (sacubitril/valsartan) Chronic heart failure (Novartis) Ibrance (palbociclib) Breast cancer (Pfizer) Lumacaftor plus ivacaftor Cystic fibrosis (Vertex) Viekira Pak * Hepatitis C (AbbVie) Evolocumab Hypercholesterolemia (Amgen and Astellas) Gardasil 9 HPV vaccine (Merck & Co.
KEY WORDS: Familial hypercholesterolemia (FH) low density lipoprotein receptor (LDL-R) Direct PCR (polymerase chain reaction) Kappa Blood Kit.